Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Glutamine + XELOX + bevacizumab + sintilimab in KRAS G12D metastatic colorectal cancer (Phase II, single arm)
ChiCTR2600130117Phase 2Not yet recruiting
- Sponsor
- Second Affiliated Hospital of Zhejiang University School of Medicine
- Start
- Aug 2026
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of glutamine, sintilimab, oxaliplatin, capecitabine and bevacizumab in colorectal cancer (CRC), sponsored by Second Affiliated Hospital of Zhejiang University School of Medicine. Primary endpoint: Objective response rate. Planned start Aug 2026; status: not yet recruiting.
02
Drugs
glutaminesintilimaboxaliplatincapecitabinebevacizumab
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on ChiCTR2600130117.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600130117.